Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis | Zendy

B. Fantin | Zendy; B. Pangon | Zendy; G. Potel | Zendy; J M Vallois | Zendy; François Caron | Zendy; A Buré | Zendy; C Carbon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis

Author(s) -

B. Fantin,

B. Pangon,

G. Potel,

J M Vallois,

François Caron,

A Buré,

C Carbon

Publication year - 1989

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.33.5.767

Subject(s) - netilmicin , aminoglycoside , ceftriaxone , in vivo , cephalosporin , medicine , pharmacology , endocarditis , antibiotics , escherichia coli , antibacterial agent , microbiology and biotechnology , chemistry , gentamicin , biology , tobramycin , biochemistry , gene

We evaluated the activities of ceftriaxone (15 mg/kg), netilmicin (6 mg/kg), and their combination given intramuscularly once daily for 4 days for the treatment of experimental Escherichia coli endocarditis in rabbits. In vitro, a greater rate of killing and an increased trough serum bactericidal titer (P less than 0.01) were achieved with the combination. In vivo, the combination had a greater bactericidal effect (P less than 0.01) and resulted in a greater number of sterile vegetations (P less than 0.05) than single-drug therapy. Thus, in vivo, an increased effect can be obtained despite a single daily dose of a long-acting cephalosporin and an aminoglycoside.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research